Using GPS for the Body® technology, Calypso can enable most clinics to offer Stereotactic Body Radiation Therapy (SBRT) prostate treatments by detecting even slight movement of the target, so clinicians can keep it in the path of Varian's precise radiation beam. Tighter treatment margins can help reduce potential side effects and may improve the quality of life for patients, escalate dose to improve disease control, or accelerate treatments with SBRT. Using real-time tracking and treatments, Calypso provides clinicians with the data to make decisions that may result in reducing treatment margins as well as side effects, even with increased dose1. Clinicians can confidently reduce the margins between the Clinical Target Volume (CTV) and the Planning Target Volume (PTV).
During the 12-15 minutes of a given fraction, radiation oncologists may not always hit the prostate at all times. When delivering only 1.8Gy using a single fraction, the potential exists for only minor damage to the surrounding tissue if the target is not precisely tracked. However, that changes with hypofractionation and, particularly, SBRT. Instead of delivering 1.8Gy per fraction, radiation oncologists are now typically delivering 7.5Gy to 10Gy per fraction. Using these increased doses, oncologists are much more fearful of potentially doing damage to the surrounding tissue. This is where relying on a superior real-time motion management technology is of utmost importance.
By working in tandem with linacs that provide accelerated treatments and a more concentrated dose delivery, the Calypso system can enable most clinics to offer SBRT prostate treatments.
*Not all features, upgrades or optional items are available in all markets.
1Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005; 294: 1233-1239.